Literature DB >> 31481254

Structural and antigenic characterization of a computationally-optimized H5 hemagglutinin influenza vaccine.

Yael Bar-Peled1, Jiachen Huang2, Ivette A Nuñez2, Spencer R Pierce1, Jeffrey W Ecker1, Ted M Ross2, Jarrod J Mousa3.   

Abstract

Influenza A virus is a leading cause of death worldwide. Viruses of the H5 subtype have the potential to induce high mortality, and no vaccines are currently available to protect against H5 influenza viruses in the event of an outbreak. Experimental vaccination with one clade 2 virus does not protect against other subclades. The computationally optimized broadly reactive (COBRA) methodology was previously used to generate a H5 hemagglutinin (HA) antigen (COBRA2) that elicited increased serological breadth against multiple clade 2 H5N1 influenza viruses. In this report, we structurally and antigenically characterized the COBRA2 HA antigen. We examined the biochemical characteristics of the COBRA2 protein and determined the protein is correctly cleaved, properly folded into a trimeric structure, and antigenically correct by probing with HA head- and stem-specific monoclonal antibodies (mAbs). We further probed the antigenicity by examining binding of a panel of H5 mouse mAbs to the COBRA2 antigen, as well as several other HA antigens. We determined the X-ray crystal structure of the COBRA2 HA antigen to 2.8 Å and the protein was observed to be in the expected trimeric form. The COBRA2 HA was structurally similar to the naturally occurring H5 HA antigens and suggests the protein folds similar to known HA structures. Overall, our data allow us to formulate a hypothesis on the mechanism of increased breadth due to vaccination with the COBRA2 HA antigen, which is that the protein incorporates antigenic sites from numerous HA antigens, and elicits mAbs with limited breadth, but with diversity in targeted antigenic sites.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibody; Hemagglutinin; Influenza; Vaccine

Mesh:

Substances:

Year:  2019        PMID: 31481254      PMCID: PMC6736729          DOI: 10.1016/j.vaccine.2019.08.062

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  37 in total

1.  Coot: model-building tools for molecular graphics.

Authors:  Paul Emsley; Kevin Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

2.  Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus.

Authors:  James Stevens; Ola Blixt; Terrence M Tumpey; Jeffery K Taubenberger; James C Paulson; Ian A Wilson
Journal:  Science       Date:  2006-03-16       Impact factor: 47.728

3.  XDS.

Authors:  Wolfgang Kabsch
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-01-22

Review 4.  The 2009 A (H1N1) influenza virus pandemic: A review.

Authors:  Marc P Girard; John S Tam; Olga M Assossou; Marie Paule Kieny
Journal:  Vaccine       Date:  2010-05-27       Impact factor: 3.641

5.  A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets.

Authors:  Brendan M Giles; Ted M Ross
Journal:  Vaccine       Date:  2011-02-12       Impact factor: 3.641

6.  PHENIX: a comprehensive Python-based system for macromolecular structure solution.

Authors:  Paul D Adams; Pavel V Afonine; Gábor Bunkóczi; Vincent B Chen; Ian W Davis; Nathaniel Echols; Jeffrey J Headd; Li-Wei Hung; Gary J Kapral; Ralf W Grosse-Kunstleve; Airlie J McCoy; Nigel W Moriarty; Robert Oeffner; Randy J Read; David C Richardson; Jane S Richardson; Thomas C Terwilliger; Peter H Zwart
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-01-22

7.  Antibody recognition of a highly conserved influenza virus epitope.

Authors:  Damian C Ekiert; Gira Bhabha; Marc-André Elsliger; Robert H E Friesen; Mandy Jongeneelen; Mark Throsby; Jaap Goudsmit; Ian A Wilson
Journal:  Science       Date:  2009-02-26       Impact factor: 47.728

8.  1918 Influenza: the mother of all pandemics.

Authors:  Jeffery K Taubenberger; David M Morens
Journal:  Emerg Infect Dis       Date:  2006-01       Impact factor: 6.883

9.  Genetic compatibility and virulence of reassortants derived from contemporary avian H5N1 and human H3N2 influenza A viruses.

Authors:  Li-Mei Chen; C Todd Davis; Hong Zhou; Nancy J Cox; Ruben O Donis
Journal:  PLoS Pathog       Date:  2008-05-23       Impact factor: 6.823

10.  Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir.

Authors:  Wouter Koudstaal; Martin H Koldijk; Just P J Brakenhoff; Lisette A H M Cornelissen; Gerrit Jan Weverling; Robert H E Friesen; Jaap Goudsmit
Journal:  J Infect Dis       Date:  2009-12-15       Impact factor: 5.226

View more
  6 in total

1.  Differential Recognition of Computationally Optimized H3 Hemagglutinin Influenza Vaccine Candidates by Human Antibodies.

Authors:  Nada Abbadi; Kaito Nagashima; Alma Pena-Briseno; Ted M Ross; Jarrod J Mousa
Journal:  J Virol       Date:  2022-08-02       Impact factor: 6.549

2.  The Pre-Existing Human Antibody Repertoire to Computationally Optimized Influenza H1 Hemagglutinin Vaccines.

Authors:  Kaito Nagashima; John V Dzimianski; Julianna Han; Nada Abbadi; Aaron D Gingerich; Fredejah Royer; Sara O'Rourke; Giuseppe A Sautto; Ted M Ross; Andrew B Ward; Rebecca M DuBois; Jarrod J Mousa
Journal:  J Immunol       Date:  2022-06-13       Impact factor: 5.426

3.  Computationally Optimized Broadly Reactive H2 HA Influenza Vaccines Elicited Broadly Cross-Reactive Antibodies and Protected Mice from Viral Challenges.

Authors:  Z Beau Reneer; Parker J Jamieson; Amanda L Skarlupka; Ying Huang; Ted M Ross
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103

Review 4.  Protein engineering strategies for rational immunogen design.

Authors:  Timothy M Caradonna; Aaron G Schmidt
Journal:  NPJ Vaccines       Date:  2021-12-17       Impact factor: 7.344

Review 5.  Next-Generation Influenza HA Immunogens and Adjuvants in Pursuit of a Broadly Protective Vaccine.

Authors:  Kaito A Nagashima; Jarrod J Mousa
Journal:  Viruses       Date:  2021-03-24       Impact factor: 5.048

Review 6.  Strategies Targeting Hemagglutinin as a Universal Influenza Vaccine.

Authors:  Brianna L Bullard; Eric A Weaver
Journal:  Vaccines (Basel)       Date:  2021-03-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.